Protagenic Therapeutics (PTIX) — Cash Flow Quality Index
Protagenic Therapeutics (PTIX) has a Cash Flow Quality Index of -0.07x as of December 2025. Operating cash flow of $-410.42K is below net income of $5.83 Million, suggesting accrual-heavy earnings not yet converted to cash. Explore cash efficiency ratio of Protagenic Therapeutics to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Protagenic Therapeutics Cash Flow Quality Index (1998–2006)
Historical Cash Flow Quality Index for Protagenic Therapeutics across 4 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check PTIX cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for Protagenic Therapeutics (1998–2006)
Year-by-year earnings quality comparison for Protagenic Therapeutics. For live market cap and the full company financial profile, see market cap of Protagenic Therapeutics.
| Year | Quality Index | Operating CF (USD) | Net Income | YoY Change |
|---|---|---|---|---|
| 2006 | 1.38x | $931.00K | $677.00K | ▼ -86.8% |
| 2001 | 10.44x | $1.50 Million | $144.00K | ▲ +238.2% |
| 2000 | 3.09x | $3.51 Million | $1.14 Million | ▲ +561.1% |
| 1998 | -0.67x | $-434.00K | $648.00K | — |